Prognostic Significance of the Cancer Stem Cell Markers CD133, CD44, and CD166 in Colorectal Cancer

REFERENCES

• Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5(9)744–749
   PubMed Web of Science ®Google Scholar
• Reya T., Morrison S. J., Clarke M. F., Weissman I. L. Stem cells, cancer, and cancer stem cells. Nature 2001; 414(6859)105–111
   PubMed Web of Science ®Google Scholar
• Jordan C. T., Guzman M. L., Noble M. Cancer stem cells. N Engl J Med 2006; 355(12)1253–1261
   PubMed Web of Science ®Google Scholar
• O'Brien C. A., Pollett A., Gallinger S., Dick J. E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445(7123)106–110
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L., Lombardi D. G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445(7123)111–115
   PubMed Web of Science ®Google Scholar
• Dalerba P., Dylla S. J., Park I. K., Liu R., Wang X., Cho R. W., Hoey T., Gurney A., Huang E. H., Simeone D. M., Shelton A. A., Parmiani G., Castelli C., Clarke M. F. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104(24)10158–10163
   PubMed Web of Science ®Google Scholar
• Boman B. M., Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 2008; 26(17)2828–2838
   PubMed Web of Science ®Google Scholar
• Rich J. N., Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell 2007; 1(4)353–355
   PubMed Web of Science ®Google Scholar
• Trumpp A., Wiestler O. D. Mechanisms of disease: cancer stem cells—targeting the evil twin. Nat Clin Pract Oncol 2008; 5(6)337–347
   PubMedGoogle Scholar
• Horst D., Kriegl L., Engel J., Kirchner T., Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008; 99(8)1285–1289
   PubMed Web of Science ®Google Scholar
• Kojima M., Ishii G., Atsumi N., Fujii S., Saito N., Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008; 99(8)1578–1583
   PubMed Web of Science ®Google Scholar
• Weichert W., Knosel T., Bellach J., Dietel M., Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004; 57(11)1160–1164
   PubMed Web of Science ®Google Scholar
• Mulder J. W., Kruyt P. M., Sewnath M., Oosting J., Seldenrijk C. A., Weidema W. F., Offerhaus G. J., Pals S. T. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994; 344(8935)1470–1472
   PubMed Web of Science ®Google Scholar
• Ngan C. Y., Yamamoto H., Seshimo I., Ezumi K., Terayana M., Hemmi H., Takemasa I., Ikeda M., Sekimoto M., Monden M. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J Surg Oncol 2007; 95(8)652–662
   PubMed Web of Science ®Google Scholar
• Visca P., Del Nonno F., Botti C., Marandino F., Sebastiani V., Di Tondo U., Donnorso R. P., Trombetta G., Filippi S., Alo P. L. Role and prognostic significance of CD44s expression in colorectal cancer. Anticancer Res 2002; 22(5)2671–2675
   PubMed Web of Science ®Google Scholar
• Weg-Remers S., Schuder G., Zeitz M., Stallmach A. CD44 expression in colorectal cancer. Ann NY Acad Sci 1998; 859: 304–306
   PubMed Web of Science ®Google Scholar
• Zavrides H. N., Zizi-Sermpetzoglou A., Panousopoulos D., Athanasas G., Elemenoglou I., Peros G. Prognostic evaluation of CD44 expression in correlation with bcl-2 and p53 in colorectal cancer. Folia Histochem Cytobiol 2005; 43(1)31–36
   PubMed Web of Science ®Google Scholar
• Gupta G. P., Massague J. Cancer metastasis: building a framework. Cell 2006; 127(4)679–695
   PubMed Web of Science ®Google Scholar
• Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell 2000; 100(1)57–70
   PubMed Web of Science ®Google Scholar
• Kuhn S., Koch M., Nubel T., Ladwein M., Antolovic D., Klingbeil P., Hildebrand D., Moldenhauer G., Langbein L., Franke W. W., Weitz J., Zoller M. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007; 5(6)553–567
   PubMed Web of Science ®Google Scholar
• Eschrich S., Yang I., Bloom G., Kwong K. Y., Boulware D., Cantor A., Coppola D., Kruhoffer M., Aaltonen L., Orntoft T. F., Quackenbush J., Yeatman T. J. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23(15)3526–3535
   PubMed Web of Science ®Google Scholar
• Merkel S., Wein A., Gunther K., Papadopoulos T., Hohenberger W., Hermanek P. High-risk groups of patients with stage II colon carcinoma. Cancer 2001; 92(6)1435–1443
   PubMed Web of Science ®Google Scholar
• O'Connell J. B., Maggard M. A., Ko C. Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96(19)1420–1425
   PubMed Web of Science ®Google Scholar